Arbli™ Lands Formulary Wins at Three Top Pediatric Hospitals
SCNX is trading near its 52-week low of $0.176 (5.9% above the low).
Summary
Scienture's Arbli™ (losartan oral suspension) has been added to formularies at three leading U.S. pediatric academic medical centers, expanding institutional adoption. This follows the product's commercial launch and sequential growth in wholesale orders. The company cites a $219M U.S. losartan market and high gross margins, suggesting meaningful revenue potential from even modest penetration. The news is a concrete commercial milestone for a micro-cap company with a market cap around $7M, and it comes just days before a 1-for-25 reverse split effective October 5, 2026. Traders should note that the reverse split may affect liquidity and price dynamics, but the formulary wins are a positive fundamental development.
At the time of this announcement, SCNX was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $0.18 to $2.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.